Turing Pharmaceuticals, a small company that generated outrage over raising the cost of an old anti-infective drug by more than 5,000%, said on Tuesday it would roll back that increase to make sure it remains affordable.
Continue Reading Below
Turing and its Chief Executive Officer Martin Shkreli became the new face of the U.S. drug pricing controversy this week, after the New York Times reported that the company had raised the price of Daraprim, a 62-year-old treatment for a dangerous parasitic infection, to $750 a pill from $13.50 after acquiring it. The medicine once sold for $1 a pill.
The story sparked outrage among patients, medical societies and Democratic presidential front-runner Hillary Clinton, who outlined on Tuesday a proposal to cap skyrocketing prescription drug costs for consumers.
"We've agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit, and we think these changes will be welcome," Shkreli told ABC World News Tonight. The final cost was still being determined, but would be less than $750 per pill.
Earlier in the day, PhRMA, the pharmaceutical industry's main lobbying group, sought to distance itself from Turing's move, posting on Twitter that the drugmaker "does not represent the values of PhRMA member companies."
Asked for further details, the lobby group noted that Turing is not one of its members, which include global drugmakers such as Merck & Co, Pfizer and Novartis.
Continue Reading Below
"PhRMA members have a long history of drug discovery and innovation that has led to increased longevity and improved lives for millions of patients," the group said in a statement. "Turing Pharmaceutical is not a member of PhRMA and we do not embrace either their recent actions or the conduct of their CEO.”
In an interview on CNBC on Monday, an unapologetic Shkreli said that Daraprim had been priced too low and that his company needed to generate profits that it would spend on new research and development. PhRMA member companies have made similar arguments on the need to price new drugs high enough to ensure that they have enough to cover their R&D investments.
Asked if he would lower the price in response to the furor, Shkreli simply responded, "No."
(Reporting by Bill Berkrot and Caroline Humer in New York, Peter Cooney in Washington)